Atypical haemolytic uraemic syndrome (aHUS) - eculizumab or ravulizumab - initial or switching authority application form (PB119)

Use this form to apply for initial or switching PBS-subsidised treatment with eculizumab or ravulizumab for aHUS.

Page last updated: 1 January 2024.
QC 21446